2025年3月最新中科院分区数据已更新，欢迎查询使用。如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
| 近期推荐： | 热 SCI论文AI润色+人工QC服务 | 热 赛默飞基础学科研究有奖问卷 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | JOURNAL OF CLINICAL ONCOLOGY J CLIN ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.9
53人评分
我要评分
声誉 9.9 影响力 9.9 速度 9.1 | |||||||||||||||||||||
| 期刊ISSN | 0732-183X | 微信扫码收藏此期刊 | ||||||||||||||||||||
| E-ISSN | 1527-7755 | |||||||||||||||||||||
| 2023-2024最新影响因子 （数据来源于搜索引擎） | 42.1 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2025年4月18日：25.449 | |||||||||||||||||||||
| 2023-2024自引率 | 2.40%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 37.4 | |||||||||||||||||||||
| JCI期刊引文指标 | 6.51 | |||||||||||||||||||||
| h-index | 494 | |||||||||||||||||||||
| CiteScore （ 2024年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://jco.ascopubs.org/ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/JCO-ASCOPUBS | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足JOURNAL OF CLINICAL ONCOLOGY的语言要求，还能让JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人得到更好的审稿体验，让稿件最大限度地被JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, USA, VA, 22314 | |||||||||||||||||||||
| 出版商 | American Society of Clinical Oncology | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | UNITED STATES | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Biweekly | |||||||||||||||||||||
| 出版年份 | 1983 | |||||||||||||||||||||
| 年文章数 | 479点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 29.70% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 96.87% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2023-2024年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2025年3月最新升级版） | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2023年12月升级版） |
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2022年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0732-183X%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2月 | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 约20% | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在JOURNAL OF CLINICAL ONCOLOGY顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial Author: Macarulla, Teresa; Ren, Zhenggang; Chon, Hong Jae; Park, Joon Oh; Kim, Jin Won; Pressiani, Tiziana; Li, Daneng; Zhukova, Lyudmila; Zhu, Andrew X.; Chen, Ming-Huang; Hack, Stephen P.; Wu, Stephanie; Liu, Bo; Guan, Xiangnan; Lu, Shan; Wang, Yulei; El-Khoueiry, Anthony B. Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 5, pp. -. DOI: 10.1200/JCO.24.00337 PubMed DOI |
| 2. | Optimizing DeepHRD Interpretability for Enhanced Clinical Decision Making Author: Li, Hui; Guo, Qin; Guo, Chengshan Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 5, pp. -. DOI: 10.1200/JCO-24-01870 PubMed DOI |
| 3. | Utilization of SDC2 gene in conjunction with SEPTIN9 gene methylation analysis for the diagnosis and efficacy assessment of colorectal cancer. Author: Xie, Rongjia; Liu, Zhuqing; Yin, Xiaolan; Yuan, Min; Luo, Xinpei; Xu, Qing Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 4_SUPPL, pp. 240-240. DOI: 10.1200/JCO.2025.43.4_suppl.240 DOI |
| 4. | Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study. Author: Segal, Neil Howard; Passhak, Maria; Koese, Fatih; Kubala, Eugen; Elez, Elena; Kawakami, Hisato; Guren, Marianne G.; Jonker, Derek J.; Xu, Rui-Hua; Riera, Jorge; Tortora, Giampaolo; Siena, Salvatore; Yeh, Yu-Min; Yusof, Mastura Md; Shiu, Kai-Keen; Starling, Naureen; Peng, Xiang; Fogelman, David R.; Adelberg, David E.; Kim, Tae Won Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 4_SUPPL, pp. LBA248-LBA248. DOI: 10.1200/JCO.2025.43.4_suppl.LBA248 DOI |
| 5. | Short-course radiation(SCRT) followed by 6 cycles of cadonilimab plus mFOLFOX6 as neoadjuvant therapy for patients with locally advanced rectal cancer (LARC): A multicenter, single arm, phase II trial (NeoCaCRT). Author: He, Wan; Huang, Jun; Liao, Guixiang; Li, Wenwen; Shen, Jing; Fu, Yuxiang; Tang, Na; He, Fang; Zhao, Yandong; Liu, Zhimin; Shi, Lishuo; Pei, Fengyun; Yao, Qijun; Zhong, Xiaoling; Zhong, Keli Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 4_SUPPL, pp. LBA210-LBA210. DOI: 10.1200/JCO.2025.43.4_suppl.LBA210 DOI |
| 6. | Effects of targeting CTMP on immunogenicity of MSI-L colon adenocarcinoma cells by metabolism and cell cycle modulation. Author: Gu, Cheng; He, Rong; Gao, Jie; Xie, Rongjia; Liu, Zhuqing; Xu, Qing Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 4_SUPPL, pp. 246-246. DOI: 10.1200/JCO.2025.43.4_suppl.246 DOI |
| 7. | Personalized ctDNA monitoring to assess the recurrence of early stage pancreatic cancer after surgery. Author: Du, Juan; Zou, Lu; Sha, Hui-zi; Tong, Fan; Ni, Jiayao; Chen, Jingjing; Bai, Xinyuan; Tang, Haochen; Kong, Xiang; Liu, Yaru; Wang, Chengyi; Hu, Meizhen Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 4_SUPPL, pp. 774-774. DOI: 10.1200/JCO.2025.43.4_suppl.774 DOI |
| 8. | Neoadjuvant cadonilimab plus anlotinib followed by surgery for locally advanced esophageal squamous cell carcinoma: A single arm, phase 2 trial. Author: Zhao, Heng; Geng, Jiayi; Zhou, Lixin; Chang, Geyun; Yan, Xiang; Yang, Fan Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 4_SUPPL, pp. TPS506-TPS506. DOI: 10.1200/JCO.2025.43.4_suppl.TPS506 DOI |
| 9. | Use of immune repertoire sequencing analysis to detect differences in treatment responses for advanced esophageal squamous cell carcinoma treated with camrelizumab and platinum-based chemotherapy. Author: Zhang, Xiaoling; Zhao, Wenqi; Du, Yunyi; Su, Fei; Wang, Hui; Zhang, Yuexiang; Ma, Ning; Yang, Wei; Yang, Bo; Liu, Min; Gao, Yangjun; Yao, Chunmei; Xu, Ning; Wang, Yu; Li, Yongai; Song, Guohua; Hu, Wenqing; Zhao, Jun Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 4_SUPPL, pp. 488-488. DOI: 10.1200/JCO.2025.43.4_suppl.488 DOI |
| 10. | Prognosis of patients with liver single-organ metastases: Updated survival results of BBCAPX-II. Author: Yuan, Ying; Zhu, Ning; Fang, Xuefeng; Zhong, Chenhan; Li, Dan; Wang, Liu-Hong; Li, Jun; Weng, Shanshan; Hu, Hanguang; Dong, Caixia; Song, Yongmao; Xu, Dong; Wang, Jianwei; Sun, Lifeng; Liao, Xiujun; Yu, Ningjuan; Zhang, Suzhan; Ding, Ke-Feng Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 4_SUPPL, pp. 157-157. DOI: 10.1200/JCO.2025.43.4_suppl.157 DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
